Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiao'er Biantong Granule (also known as Xiao'er Tongbian Granule) is a traditional Chinese medicine (TCM) granule developed for the treatment of pediatric functional constipation, particularly for cases with traditional Chinese medicine dyspepsia syndrome (food accumulation syndrome). Formulated from a clinical experience prescription of Dr. Chen Yonghui, the herbal mixture contains active ingredients such as Atractylodes macrocephala (白术), Aurantii Fructus (枳壳), Magnoliae Officinalis Cortex (厚朴), and Raphani Semen (莱菔子) to invigorate the spleen, regulate qi, and promote digestion and defecation. Originally developed as Xiao'er Biantong Granule, it was approved by the National Medical Products Administration (NMPA) of China in August 2026 under the name Xiao'er Tongbian Granule as a Class 1.1 TCM innovative drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiao'er Biantong Granule.